<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00789126</url>
  </required_header>
  <id_info>
    <org_study_id>VX08-509-002</org_study_id>
    <nct_id>NCT00789126</nct_id>
  </id_info>
  <brief_title>Single and Multiple Dose Escalation Study of VX-509 in Healthy Subjects</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Single-Dose Escalation Study and Multiple-Dose Escalation Study of VX-509 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vertex Pharmaceuticals Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vertex Pharmaceuticals Incorporated</source>
  <brief_summary>
    <textblock>
      Study to evaluate the safety and tolerability of single ascending doses and multiple&#xD;
      ascending doses of VX-509 administered to healthy male and female subjects&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part A of the study will evaluate the safety and tolerability, PK, and PD of single ascending&#xD;
      doses of VX-509.&#xD;
&#xD;
      Part B will evaluate the safety and tolerability, PK, and PD of multiple ascending doses of&#xD;
      VX-509 administered for 14 days.&#xD;
&#xD;
      A total of 72 subjects will be enrolled: 36 subjects in Part A and 36 subjects in Part B.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability as measured by adverse events (AEs) and clinically relevant changes in laboratory values, vital signs, electrocardiograms (ECGs), and physical examination variables</measure>
    <time_frame>Specified timepoints in the protocol</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) parameters (Cmax, AUC, t1/2, tmax)</measure>
    <time_frame>Specified timepoints in the protocol</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (PD)parameters of percent and actual change from baseline for a panel of JAK-dependent biomarkers</measure>
    <time_frame>Specified timepoints in the protocol</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VX-509</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy, non-smoking male or healthy, non-smoking, non-pregnant female&#xD;
&#xD;
          -  Able to comply with study procedures&#xD;
&#xD;
          -  Male subjects must agree to use 2 highly effective methods of contraception&#xD;
&#xD;
          -  Female subjects must be of documented non-child-bearing potential or must agree to use&#xD;
             2 highly effective methods of contraception&#xD;
&#xD;
          -  No clinically significant abnormal results for physical examination or clinically&#xD;
             significant out of range laboratory results&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of any significant illness&#xD;
&#xD;
          -  Illness within 5 days before Day 1&#xD;
&#xD;
          -  Regular treatment with any medications&#xD;
&#xD;
          -  Any type of tobacco or nicotine use&#xD;
&#xD;
          -  History of drug or alcohol abuse or addiction within 2 years before Screening visit&#xD;
&#xD;
          -  Positive tuberculin skin test at Screening&#xD;
&#xD;
          -  Female subjects who are lactating or planning to become pregnant during the study&#xD;
             period or within 90 days of last dose of study drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Spencer-Green, MD, MS</last_name>
    <role>Study Director</role>
    <affiliation>Vertex Pharmaceuticals Incorporated</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <study_first_submitted>November 7, 2008</study_first_submitted>
  <study_first_submitted_qc>November 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2008</study_first_posted>
  <last_update_submitted>February 18, 2009</last_update_submitted>
  <last_update_submitted_qc>February 18, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 19, 2009</last_update_posted>
  <responsible_party>
    <name_title>George Spencer-Green, MD, MS</name_title>
    <organization>Vertex Pharmaceuticals</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

